Biotron Ltd (ASX: BIT) Share Price and News





  (20 mins delayed)

52 Week Range


1 Year Return


Biotron Ltd Chart and Price Data

Fundamentals Data provided by Morningstar.

Data provided by Morningstar.
Market Cap $29.78 million
P/E Ratio N/A
Dividend Yield 0.00%
Shares Outstanding 902.28 million
Earnings per share -0.005
Dividend per share N/A
Year To Date Return -64.95%
Earnings Yield N/A
Franking -
Share Price

Day Change

52 Week Range


Yesterday's Close

Today's Open

Days Range



Avg. Volume (1 month)


as at 24 Feb 3:44pm

  • Biotron Ltd (ASX: BIT)
    Latest News

    A woman jumps for joy with a rocket drawn on the wall behind her.
    Healthcare Shares

    Guess which ASX healthcare stock is rocketing almost 50% on Friday

    This stock is avoiding the market weakness on Friday. But why?

    Read more »

    A group of medical researchers stands side by side with each other wearing white coats in their research laboratory with scientific equipment in the background.
    Share Gainers

    Biotron share price rockets 38% on COVID trial results

    Successfully treating COVID-19 is still in the sights of biotech researchers.

    Read more »

    A happy doctor in a white coat dancing due to his excitement over the EBOS acquisition
    Healthcare Shares

    The Biotron (ASX:BIT) share price just exploded 86% on COVID drug update

    Here's the latest news from the biotechnology company...

    Read more »

    high share price
    Share Gainers

    Why Biotron, Fortescue, Ramelius, & Temple & Webster are storming higher

    Biotron Limited (ASX:BIT) and Fortescue Metals Group Limited (ASX:FMG) shares are two of four storming notably higher on Monday...

    Read more »

    Share Market News

    Biotron share price rockets 47% higher on COVID-19 compound testing update

    The Biotron Limited (ASX:BIT) share price rocketed 47% higher on Monday after updating the market on its COVID-19 compound tests...

    Read more »

    Biotechnology graphics
    Share Market News

    Biotron share price rockets 30% on latest antiviral drug data

    The Biotron Limited (ASX: BIT) share price soared by 30% today, after the biotechnology company released new data regarding the…

    Read more »

    a woman
    Share Market News

    Why the Biotron share price has soared 22% higher today

    The Biotron Limited (ASX: BIT) share price is soaring higher this morning after the company released more data in relation…

    Read more »

    a woman
    Share Gainers

    Why Biotron, Karoon Energy, Pro Medicus, & WiseTech Global are pushing higher

    Pro Medicus Limited (ASX:PME) and WiseTech Global Ltd (ASX:WTC) shares are two of four pushing higher on Thursday. Here's why...

    Read more »

    a woman
    Share Gainers

    These ASX shares are fighting the spread of coronavirus

    Some ASX shares are fighting coronavirus with demand for their products accelerating along with the spread of the virus. We…

    Read more »

    a woman
    52-Week Highs

    Why CSL and these ASX shares just hit 52-week highs

    CSL Limited (ASX:CSL) and these ASX shares have just hit record highs. Here's why they have been storming higher in…

    Read more »

    a woman
    Share Gainers

    Biotron share price jumps 70% in two days on coronavirus hopes

    The Biotron Limited (ASX:BIT) share price has rocketed higher this week after it revealed that it is testing its compounds against the coronavirus...

    Read more »

    a woman
    Share Gainers

    Why Biotron, De Grey Mining, Kathmandu, & Nick Scali are storming higher

    The Biotron Limited (ASX:BIT) share price and the Nick Scali Limited (ASX:NCK) share price are two of four storming higher on Friday...

    Read more »

    BIT ASX Announcements

    An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.

    DateAnnouncementPrice Sensitive?TimeNo. of PagesFile Size

    About Biotron Ltd

    Biotron Ltd is a biotechnology company. It is engaged in the funding and management of intermediate and applied biotechnology research and development projects. Its antiviral drug is BIT225, which is in Phase II clinical trials for the treatment of HIV-1 and hepatitis C virus infections. Geographically, it operates only in Australia through biotechnology segment.

    BIT Share Price History Data provided by Morningstar.

    Data provided by Morningstar.
    Date Close Change % Change Volume Open High Low
    17 Jul 2024 $0.03 $0.00 0.00% 247,372 $0.03 $0.04 $0.03
    16 Jul 2024 $0.03 $0.00 0.00% 479,194 $0.04 $0.04 $0.03
    15 Jul 2024 $0.04 $0.00 0.00% 566,649 $0.03 $0.04 $0.03
    12 Jul 2024 $0.03 $0.00 0.00% 2,300,488 $0.03 $0.03 $0.03
    11 Jul 2024 $0.03 $-0.01 -25.64% 6,152,454 $0.04 $0.04 $0.03
    10 Jul 2024 $0.04 $0.00 0.00% 994,640 $0.04 $0.04 $0.04
    09 Jul 2024 $0.04 $0.00 0.00% 34,628 $0.04 $0.04 $0.04
    08 Jul 2024 $0.04 $0.00 0.00% 592,187 $0.04 $0.04 $0.04
    05 Jul 2024 $0.04 $0.00 0.00% 361,737 $0.04 $0.04 $0.04
    04 Jul 2024 $0.04 $0.00 0.00% 187,627 $0.04 $0.04 $0.04
    03 Jul 2024 $0.04 $0.00 0.00% 1,029,327 $0.04 $0.04 $0.04
    02 Jul 2024 $0.04 $0.00 0.00% 672,018 $0.04 $0.04 $0.04
    01 Jul 2024 $0.04 $0.00 0.00% 1,670,520 $0.04 $0.04 $0.04
    28 Jun 2024 $0.04 $0.00 0.00% 1,794,468 $0.04 $0.04 $0.04
    27 Jun 2024 $0.04 $0.00 0.00% 1,579,897 $0.04 $0.04 $0.04
    26 Jun 2024 $0.04 $-0.01 -21.28% 11,211,375 $0.05 $0.05 $0.04
    25 Jun 2024 $0.05 $0.00 0.00% 1,773,949 $0.05 $0.05 $0.04
    24 Jun 2024 $0.05 $0.00 0.00% 871,500 $0.05 $0.05 $0.04
    21 Jun 2024 $0.05 $0.00 0.00% 708,385 $0.04 $0.05 $0.04
    20 Jun 2024 $0.05 $0.00 0.00% 3,841,150 $0.05 $0.05 $0.04
    19 Jun 2024 $0.05 $0.00 0.00% 19,010,984 $0.06 $0.07 $0.05
    18 Jun 2024 $0.05 $0.00 0.00% 299,209 $0.05 $0.05 $0.05

    Directors & Management Data provided by Morningstar.

    Data provided by Morningstar.
    Name Title Start Date Profile
    Mr Michael J Hoy Non-Executive DirectorNon-Executive Chairman Feb 2000
    Mr Hoy has more than 30 years' corporate experience in Australia,the United Kingdom, USA and Asia. He is Chairman of Lipotek Pty Limited and a former director of John Fairfax Holdings Limited and FXF Trust. Mr Hoy has been a director since 7 February 2000 and Chairman since 16 March 2000.
    Mr Robert Bain Thomas Non-Executive Director Mar 2012
    Mr Thomas has over 35 years' experience in the securities industry, with Potter Partners (now UBS), County NatWest and Citigroup. He is the chairman of Starpharma Holdings Limited and a director of Clarity Pharmaceuticals Limited. He chairs Grahger Retail Securities Pty Ltd and is a director of O'Connell Street Associates Pty Limited.He is a Master Stockbroker. Mr Thomas was appointed as a director on 7 March 2012.
    Dr Michelle Miller Managing Director Jun 2002
    Dr Miller has worked for over 25 years in the bioscience industry, with experience in commercial drug development. She completed her PhD in the Faculty of Medicine at Sydney University investigating molecular models of cancer development. Her experience includes several years at Johnson & Johnson developing anti-HIV gene therapeutics through preclinical research to clinical trials. She has finance industry experience from time spent as an Investment Manager with a specialist bioscience venture capital fund. Dr Miller was appointed as Managing Director on 21 June 2002.
    Dr Susan Margaret Pond Non-Executive Director Mar 2012
    Dr Pond has a scientific and commercial background having held executive positions in the biotechnology and pharmaceutical industry for 12 years, recently as chairman and managing director of Johnson & Johnson Research Pty Limited (2003 - 2009). Previous non-executive positions include chair of AusBiotech Limited and director of Australian Nuclear Science and Technology Organisation, Wound Management Innovation CRC and Australian Academy of Technological Sciences and Engineering (ATSE). Dr Pond also served as a board member of Commercialisation Australia and Innovation Australia. Dr Pond is currently director of the Trusted Autonomous Systems Defence Cooperative Research Centre, Vectus Biosystems Ltd and the Australian Phenomics Network. She is a member of the Council of the Queensland University of Technology, the Academy of Technological Sciences & Engineering, the Academy of Health and Medical Sciences and the Royal Society of New South Wales. She obtained specialist clinical credentials in internal medicine, clinical pharmacology and clinical toxicology and held academic appointments at the University of California San Francisco and the University of Queensland before joining industry. Dr Pond was appointed as a director on 7 March 2012.
    Professor Stephen Alister Locarnini Non-Executive Director Oct 2018
    Mr Locarnini is a past director of the World Health Organisation (WHO) Regional Reference Laboratory for Hepatitis B and D for the Western Pacific Region (WPRO). His current major research interests include viral hepatitis, hepatitis vaccines and antiviral chemotherapy with an emphasis on the basic virology of the various agents of hepatitis, the molecular pathogenesis of hepatitis, as well as prevention and public health control measures. Curative treatments for Hepatitis B infections with antiviral agents represent the current focus for Professor Locarnini who is also interested in intellectual property issues when applied to clinical and diagnostic virology. He is a named inventor on over 20 internationally granted patents. He worked at the Victorian Infectious Diseases Reference Laboratory (VIDRL, originally Fairfield Hospital Virus Laboratory) from 1989, as Director of Laboratory Services from 1990 to 1998 and, in 1993, he oversaw the amalgamation of all the Fairfield Laboratories into the one service of the VIDRL. He subsequently assumed the position of Head, Research & Molecular Development of VIDRL when the laboratory relocated to Melbourne Health in 1998. Professor Locarnini is the recipient of numerous awards including the European Association for the Study of Liver Disease (EASL) International Recognition Award in 2010, the Malaysian Liver Foundation's Medal for work on Viral Hepatitis in 2003 and the Gastroenterological Society of Australia (GESA) Distinguished Research Prize in 2013. In 2019 he received the William H. Prusoff HEP DART Lifetime Achievement Award. He is author of 289 peer-reviewed articles, 24 invited editorials and 100 book chapters and reviews and every year delivers numerous invited, plenary, and named lectures at major international meetings and conferences. Professor Locarnini currently has an academic appointment at the University of Melbourne. He is a member of the Scientific Advisory Board of a number of emerging as well as established pharmaceutical and biotechnology companies. In 2017, he co-founded the biotech start-up company CLEAR-B with the Morningside-Newton Investment group in Boston, USA focusing on curative strategies for chronic Hepatitis B.
    Mr Peter James Nightingale Company Secretary Feb 1999
    Peter James Nightingale Company Secretary

    Top Shareholders Data provided by Morningstar.

    Data provided by Morningstar.
    Name Shares Capital
    Jey Investment Pty Ltd 24,240,000 2.69%
    Rookharp Capital Pty Limited 15,267,176 1.69%
    Umbiram Pty Ltd <Michael Hoy Super Fund A/C> 11,217,352 1.24%
    Dr Angela Fay Dulhunty 10,000,000 1.11%
    Citicorp Nominees Pty Limited 9,464,208 1.05%
    Fordholm Investments Pty Ltd <Fordholm Super Fund A/C> 9,300,000 1.03%
    DNS Accounting and Law Consultancy Pty Ltd 9,089,820 1.01%
    Mr Travis Fountain 8,897,892 0.99%
    Attollo Copia Pty Ltd <F A Pires Super Fund A/C> 7,770,678 0.86%
    Sked Proprietary Limited <Sked Superannuation Fund A/C> 7,462,000 0.83%
    William John Dunn 7,300,000 0.81%
    Pathold No 222 Pty Ltd 7,010,000 0.78%
    Armco Barriers Pty Ltd 7,000,000 0.78%
    Mrs Zi Juan QI <Chen Family A/C> 5,878,488 0.65%
    Edstop Pty Limited <Superannuation Fund A/C> 5,845,906 0.65%
    Mrs Yang Wang <Aust West Coast Travel A/C> 5,108,912 0.57%
    Standby Forty-Six Pty Limited 5,000,000 0.55%
    Scott's A V Pty Ltd <Scotts Acorn EMP S/F A/C> 4,918,000 0.55%
    Mr Travis Paul Gloury 4,819,355 0.53%
    Vicex Holdings Proprietary Limited <Vicex Super A/c> 4,600,000 0.51%